

emyria

ASX : EMD

Investor update for the full year ended 30 June 2026

Investor Webinar

September 2026



Disclaimer

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.

Who are we?

Emyria is addressing a significant and escalating gap in the mental healthcare market



Emyria is building a national network of clinics specialising in delivery of Psychedelic Assisted Therapy for PTSD and Treatment Resistant Depression



Worldwide First Mover Advantage


A Regulated Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions



Australia


is the FIRST jurisdiction in the world to reschedule two promising treatments¹

MDMA-assisted therapy



For PTSD

Psilocybin-assisted therapy



For Depression

This regulation change has created a Multi-billion Dollar Industry.

SOURCES

¹ <https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists>

Major Funders are spending Hundreds of Millions each year on mental health



Private Health Insurers



\$2B

spent by Medibank on mental health hospitalisations in last 10 years,

\$219M/yr

in 2024 alone. ¹

Only 26% of insured adults

Department of Veterans' Affairs



The Government spends

\$300M/yr on veteran mental health each year. ²

Almost **three in four** (veterans) are estimated to have met criteria for a mental disorder at some stage in their lifetime. ³

Other Insurers



Life insurers ... paid out more than

\$2.2B in 2024

for retail mental health claims in 2024 ⁴

SOURCES:

1. <https://www.heraldsun.com.au/health/mental-health/alarming-research-shows-extent-of-mental-health-crisis-in-australia/news-story/66f6937a316f9dd54673c5a6f692b232>


2. https://www.dva.gov.au/sites/default/files/twrp_mhpr.pdf

3. <https://www.dva.gov.au/news/latest-stories/report-hospitalisations-suicidality-and-self-harm-released#:~:text=The%20Australian%20Government%20is%20committed,%E2%80%93%20Veterans%20&%20Families%20Counselling%20Service.>

4. <https://www.abc.net.au/news/2025-07-16/spike-in-mental-health-illness-claims-super-funds-delay-payouts/105531022>

Patient Journey | Treatment Model + Bed Capacity

Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up



Significant Total Addressable Market¹

~1,100,000 adults in Australia have major depression (~4%)
~1,500,000 adults in Australia have PTSD (~7%)

Each dosing day ~\$10,000 revenue

PTSD Total treatment cost / patient ~\$33,000

Treatment Resistant Depression cost / patient ~\$22,000


BED CAPACITY		
Clinic	Beds	Dosing days / week
Perth (x2)	8	40
Brisbane	3	15
Melbourne	3	15
Sydney	4	20*
=	18	90

*When operational

SOURCES:
1) <https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and-wellbeing/latest-release#key-statistics>

Typical timeline to projected clinic profitability

Current Clinic Status



Perth Clinics	+
Brisbane	+
Mornington (VIC)	+
Sydney	+



Full year ended 30 June in Review: A Year of Demonstrable Growth



	Yearly Revenue (\$AUD)	Clinics Operational*	Beds Operational*	Clinicians Trained * (Australia-wide)	Total Authorised Prescribers ** (Australia-wide)	Total Patients Treated
FY25	\$1.39M	1	4	~30	6	24
FY26	\$4.05M	5	18	~145	17	138
	+191%	+4	+14	+333%	+183%	+475%

*Includes those announced not yet operational

**Includes those trained / approved after 30 June 2026

+ Medibank agreement, national funding

+ Government payer access announced (DVA funding)

+ Clinically significant results from Emyria's PTSD & treatment resistant depression program

+ Launch of Empax Global Partnership Program

Emyria | Looking Ahead

Delivering on commitments to shareholders



Core focus areas for financial year 2027:

- Increase clinic utilisation of existing clinics in Australia
- Continued expansion of Australian clinic network
- Continued pursuit of additional reimbursement pathways
- Continue progressing drug development programs through targeted, non-dilutive funding
- Explore opportunities in jurisdictions outside Australia, including New Zealand and the USA
- Grow our Empax Global Partnership Program

Significant momentum in global psychedelic drug treatments

Recent macro catalysts provide significant tailwinds for Emyria



Compass stock heads north on psychedelic's Phase III TRD success

Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA's blessing.

Big Pharma And Psychedelic Medicine—Eli Lilly's \$3.8 Billion Bet

Forbes

Trump announces reforms to accelerate access to psychedelic drug treatments

President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaine

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

PSYCHEDELIC ALPHA

News

New Zealand drugs regulator approves use of MDMA to treat severe PTSD

New Zealand decision follows Australian approval in 2023 of psychedelics to treat PTSD and treatment-resistant depression

The Guardian

Compass Pathways Phase 3 Results Raise Hopes For FDA Approval Of Psilocybin

Forbes

AMERICAN PSYCHOLOGICAL ASSOCIATION

FEATURE

The emergence of psychedelics as medicine

A look at the potential of MDMA, ketamine, and psilocybin to help people with treatment-resistant mental health conditions

Emyria moves on clinical drugs play

BUSINESSNEWS

Emyria is well positioned to leverage this momentum, creating the infrastructure and writing the playbook for psychedelic drug delivery

SOURCES

1. <https://psychedelics.berkeley.edu/clinical-trials-map>

Investor Q+A



Greg Hutchinson

ghutchinson@emyria.com

**Mary-Ann
Rennie**

mrennie@emyria.com

**Investor /
Media Inquiries**

investors@emyria.com

emyria



**Visit Our
Investor Hub**